BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 28, 2010
 |  BioCentury  |  Emerging Company Profile

Arreseto: Blocking Fibroblasts

Arresto aiming to block fibroblasts central to cancer, fibrosis and inflammation

Arresto Biosciences Inc. is developing allosteric inhibitors of enzymes found in the extracellular matrix. Because the company's lead mAb inhibits the formation of pathologic stroma, it offers new mechanisms for treating cancer and fibrosis. In cancer, the mAb should be complementary to drugs that target tumor cells. In fibrotic diseases, the logic is that a more complete blockade of the processes that lead to fibrosis should give the compound the potential to reverse, not just halt, disease.

AB0024, a humanized mAb against lysyl oxidase-like 2 (LOXL2), is expected to enter Phase I testing for advanced solid tumors next month. Arresto is in discussions with FDA about a second trial in idiopathic pulmonary fibrosis (IPF) that could begin in 4Q.

The inspiration for Arresto came from work published in Nature in 2006 by Amato Giaccia, a professor of radiation oncology at Stanford University. Giaccia's group showed metastasis could be inhibited by blocking lysyl oxidase (LOX), an enzyme that plays a role in the formation of stroma in tumors.

LOX belongs to a family of five enzymes involved in maintenance and homeostasis of tissues....

Read the full 910 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >